Atlas Trials

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Clinical trial NCT03401853 · TERMINATED

Trial details

NCT number
NCT03401853
Sponsor
University of Washington
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular Lymphoma
Start date
2018-03-23
Primary completion
2023-12-19
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.